Jul 19 |
Lisata to use Haystack’s MRD tests for pancreatic cancer therapy trial
|
Jul 18 |
Lisata to use Haystack technology to evaluate pancreatic cancer asset certepetide
|
Jul 18 |
Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy
|
Jul 18 |
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
|
Jul 18 |
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
|
Jul 16 |
Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why
|
Jul 16 |
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
|
Jul 10 |
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
|
Jun 14 |
Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial
|
Jun 13 |
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
|